Factors, such as rising prevalence of tuberculosis, growing initiative from government organization for tuberculosis awareness, collaboration between academic and private players for novel drug development, and rising incidence of MDR and XDR cases in developing countries, are propelling the growth of the market studied.
According to the WHO’s 2020 Global Tuberculosis (TB) Report, a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent. Overall, the global burden of TB and MDR-TB is a challenge for leading medical regulatory institutions. The active interest of both medical communities and government alike, in curbing TB, is expected to increase the number of diagnoses for TB. This is, in turn, driving the growth of the global anti-tuberculosis therapeutics market, supported by the increasing global prevalence of TB and MDR-TB.
Key Market Trends
Hospitals/Clinics are Expected to Witness the Fastest Growth in the Coming Future
The WHO’s strategy to prevent TB includes engaging all relevant healthcare providers in tuberculosis (TB) care, while control through public-private mix approach remains an essential component of the strategy. The TB prevalence rate is more in countries, like China, India, and Africa, hence, the governments of these respective countries are trying to decrease the rate by increasing government initiatives and the number of hospitals.
As per 2019 Global Tuberculosis Report by the WHO, developing countries accounted for most of the global total TB cases, including India (27%), China (9%), Indonesia (8%), and the Philippines (6%). The developing countries mostly rely on the hospitals for healthcare access. Hence high incidence in the regions will boost the market in hospitals and clinics.
Asia-Pacific is Expected to be the Largest Market Over the Forecast Period
As per 2019 Global Tuberculosis Report by the WHO, geographically, most TB cases in 2018 were in the WHO regions of South-East Asia (44%), Africa (24%) and the Western Pacific (18%). As a result, a large number of cases are found in the Asia-Pacific region, which is expected to help the region dominate the market. Moreover, most of the global pharmaceutical companies have penetrated in developing countries like India and China, which is also expected to increase the availability of therapeutics and boost the market growth.
The anti-tuberculosis therapeutics market is highly consolidated, with very few companies holding a substantial market share. With the rising focus of the healthcare sector on the development of novel drugs and the growing investment in the R&D, imore small to mid-sized companies are estimated to enter into the market in the coming future.
Currently, companies such as Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, and Johnson and Johnson hold the largest market share.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support